This launch consists of product packaged in bottles to a number of customers. The company expects to initiate its full-scale over-the-counter (OTC) launch of product in blister packaging to its retail and wholesale customers in store brand or own label before the end of its current fiscal year.
Mucinex® 600mg tablets (Guaifenesin Extended-Release Tablets, 600mg), an expectorant indicated to relieve chest congestion and make coughs more productive, has estimated annual sales of approximately $135 million.
Perrigo's Chairman and CEO Joseph C. Papa stated, "This is another great new product launch for our team and is representative of Perrigo's unwavering commitment to make significant investments necessary to bring complex new products to market. Perrigo continues to focus on making quality healthcare more affordable by expanding our customers' offerings of high quality, value priced products."
Perrigo Announces the Launch of Guaifenesin Extended-Release 600mg Tablets -- to Compare to Mucinex 600mg
Perrigo Company (Nasdaq: PRGO; TASE) announced that it has initiated shipments of its Guaifenesin Extended-Release Tablets, 600mg (a generic version of Mucinex 600mg tablets) product.
Apr 13, 2012
Companies in this article